The invention relates to a liquid composition comprising a GLP-1 agonist or/and a pharmacologically tolerable salt thereof and optionally at least one pharmaceutically acceptable adjuvant. The liquid composition is characterised in that it contains methionine optionally as add-on therapy with metformin and/or long-acting insulins/insulin derivatives.

A method for the prevention of hypoglycaemia in diabetes mellitus type 2 comprising administering (a) desPro36Exendin-4(1-39)-Lys6-NH2 or/and a pharmaceutically acceptable salt thereof and (b) metformin or/and a pharmaceutically acceptable salt thereof  to a subject in need thereof.

A method for the prevention of hypoglycaemia in diabetes mellitus type 2 comprising administering (a) desPro36Exendin-4(1-39)-Lys6-NH2 or/and a pharmaceutically acceptable salt thereof and (b) metformin or/and a pharmaceutically acceptable salt thereof  to a subject in need thereof.

Liquid composition comprises a glucagon-like peptide-1 (GLP-1) agonist and/or its salt an insulin and/or its salt optionally at least one adjuvant and methionine. Independent claims are also included for: (1) a combination comprising a first pharmaceutical composition and a second pharmaceutical composition and optionally at least one additional pharmaceutical composition each having at least one insulin and at least one GLP-1 agonist where at least one insulin and/or at least one GLP-1 agonist ...

A liquid composition comprising a GLP-1 agonist or/and a pharmacologically tolerable salt thereof an insulin or/and a pharmacologically tolerable salt thereof and optionally at least one pharmaceutically acceptable excipient wherein the composition comprises methionine as add-on therapy with metformin where appropriate.